These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21831448)

  • 1. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Kondo DG; Sung YH; Hellem TL; Fiedler KK; Shi X; Jeong EK; Renshaw PF
    J Affect Disord; 2011 Dec; 135(1-3):354-61. PubMed ID: 21831448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression.
    Kondo DG; Forrest LN; Shi X; Sung YH; Hellem TL; Huber RS; Renshaw PF
    Amino Acids; 2016 Aug; 48(8):1941-54. PubMed ID: 26907087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
    Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
    J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):241-250. PubMed ID: 38700708
    [No Abstract]   [Full Text] [Related]  

  • 7. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder.
    Iosifescu DV; Bolo NR; Nierenberg AA; Jensen JE; Fava M; Renshaw PF
    Biol Psychiatry; 2008 Jun; 63(12):1127-34. PubMed ID: 18206856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study.
    Hellem TL; Sung YH; Shi XF; Pett MA; Latendresse G; Morgan J; Huber RS; Kuykendall D; Lundberg KJ; Renshaw PF
    J Dual Diagn; 2015; 11(3-4):189-202. PubMed ID: 26457568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents.
    Mayes TL; Bernstein IH; Haley CL; Kennard BD; Emslie GJ
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):513-6. PubMed ID: 21186970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
    Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.
    Durgam S; Chen C; Migliore R; Prakash C; Edwards J; Findling RL
    Paediatr Drugs; 2018 Aug; 20(4):353-363. PubMed ID: 29633166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
    Findling RL; McCusker E; Strawn JR
    J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
    [No Abstract]   [Full Text] [Related]  

  • 15. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
    McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
    J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
    [No Abstract]   [Full Text] [Related]  

  • 17. Measures of Connectivity and Dorsolateral Prefrontal Cortex Volumes and Depressive Symptoms Following Treatment With Selective Serotonin Reuptake Inhibitors in Adolescents.
    Lee KH; Shin J; Lee J; Yoo JH; Kim JW; Brent DA
    JAMA Netw Open; 2023 Aug; 6(8):e2327331. PubMed ID: 37540512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression.
    Kanekar S; Ettaro R; Hoffman MD; Ombach HJ; Brown J; Lynch C; Sheth CS; Renshaw PF
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.
    Wagner KD; Ambrosini P; Rynn M; Wohlberg C; Yang R; Greenbaum MS; Childress A; Donnelly C; Deas D;
    JAMA; 2003 Aug; 290(8):1033-41. PubMed ID: 12941675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.